

Immunology of Major Depression

Norbert Müller

Department of Psychiatry and Psychotherapy, Ludwig-Maximilian University of Munich, Munich, Germany

Key Words

Inflammation · Major depression · Psychoneuroimmunology

Abstract

High levels of several proinflammatory components of the immune system, such as interleukin-6, C-reactive protein, tumor necrosis factor (TNF)- α , or neopterin in patients suffering from major depression (MD) point to the involvement of an inflammatory process in the pathophysiology of MD. The direct and indirect effects of cytokines on neurotransmitter storage and release – mediated by microglia cells and astrocytes – are discussed. The tryptophan/kynurenine metabolism is one of the indirect mechanisms because the enzyme indoleamine 2,3-dioxygenase – a key enzyme of this metabolism in the central nervous system – is driven by pro- and anti-inflammatory cytokines and degrades serotonin. Moreover, neuroactive kynurenines such as kynurenic acid and quinolinic acid act on the glutamatergic neurotransmission as N-methyl-D-aspartate antagonists and agonists, respectively. Alterations of the serotonergic, noradrenergic and glutamatergic neurotransmission have been shown with low-level neuroinflammation and may be involved in symptom generation. Epidemiological and clinical studies show a role for inflammation as a risk factor for MD. A large-scale epidemiological study in MD clearly demonstrates that severe infections and autoimmune disorders are lifetime risk factors for MD. The vulnerability-stress-inflammation model matches with this view as stress may increase proinflammatory cytokines and even contribute to a lasting proinflammatory state. Further support comes from the therapeutic ben-

efit of anti-inflammatory medications such as the cyclo-oxygenase-2 inhibitors, TNF- α antagonists and others, and the anti-inflammatory and immunomodulatory intrinsic effects of antidepressants.

© 2014 S. Karger AG, Basel

Introduction

Activation of the inflammatory response system in major depression (MD) is well documented [1–5]. Two recent meta-analyses clearly showed elevated interleukin (IL)-6 levels in patients with MD [6, 7]. However, the findings of the two meta-analyses differed regarding levels of the inflammatory markers C-reactive protein (CRP), IL-1, IL-1RA and tumor necrosis factor (TNF)- α . In general, the inflammatory response system appears to be activated, but the levels of the different markers vary across studies. MD is a disorder often triggered by stress. It has been shown that – often based on genetic disposition – early-life stress or separation stress are associated with an increase of proinflammatory cytokines leading to an activation of the immune system and proinflammatory prostaglandins. Prostaglandin E2 (PGE2) is an important mediator of inflammation [8]. Increased PGE2 in the saliva, serum and cerebrospinal fluid (CSF) of depressed patients has been described previously [9–12]. The enzyme cyclooxygenase-2 (COX-2) is involved in the function of PGE2 in the inflammatory pathway. In the brain, the activation of microglia cells and astrocytes is crucial, because proinflammatory molecules are produced and released in

the brain. The interactions between the immune system and neurotransmitters, the tryptophan/kynurenine system, and the glutamatergic neurotransmission are further links between stress, depression and the immune system. Accordingly, anti-inflammatory therapy, e.g. with the COX-2 inhibitor celecoxib, is effective in depression.

The roles of microglial cells and astrocytes as mediators of inflammation in the brain are discussed, as is the influence of a disturbed blood-brain barrier (BBB) in facilitating the invasion of inflammatory molecules and immune cells, including monocytes, T and B cells.

The Cellular Basis of Inflammation in the Central Nervous System

Microglia cells and astrocytes have been shown to play a central role in regulating neuroinflammation [13, 14]. Astrocytes comprise approximately 80% of brain cells and are the most abundant type of glial cells in the central nervous system (CNS), while microglial cells represent about 15% of brain cells. Astrocytes have a strategic location: they are in close contact with CNS resident cells (neurons, microglia, oligodendrocytes and other astrocytes) and are part of the immune and inflammatory systems in the CNS. Among the cytokines, TNF- α , interferon (IFN)- γ , IL-1 and IL-6 are the main astrocytic activators [14]. Astrocytes are strongly involved in increased BBB permeability, endothelial cell activation, monocyte and microglia activation, and B cell survival and differentiation. Astrocytes produce and release a series of chemokines and are thus involved in the recruitment of monocytes and macrophages, dendritic cells and T and B cells in the CNS.

Astrocytes, however, also store and release neurotransmitters [15]. For example, an important function of astrocytes is the regulation and storage of glutamate, which is actively transported into astrocytes [16]. Therefore, astrocytes play a role not only as immune regulators and hosts of kynurenine metabolism, but also in the bioavailability of neurotransmitters including glutamate, the most abundant neurotransmitter, which is involved in psychiatric disorders such as MD.

BBB Disturbance in MD

By far the most studies of biological parameters, including immune parameters in MD, have examined components of blood cells and serum, although the CSF reflects disturbances in the CNS much better. During acute

inflammation, immune cells invade the CNS parenchyma through the disturbed BBB, i.e. through the endothelium of the small vessels and the tight junctions of astrocytes around the vessels. This invasion is mediated by cytokines, chemokines, adhesion molecules and other mediators of inflammation. Signs of inflammation in the CNS are a disturbance of the BBB, increased immunoglobulins and, especially in acute inflammatory states, an increase in the cell number in the CSF.

Analysis of the CSF is the gold standard for diagnosing CNS inflammatory disorders [17, 18]. The rough method of 'routine' analysis of CSF parameters, however, only discovers gross changes in the CSF. More subtle changes in the CSF of MD patients may occur in a higher percentage of patients. Pathological changes in the CSF were observed in a subgroup of around 25–30% of patients suffering from MD [19–21]. These changes included an increased production of IgG and an increased BBB permeability, as is found in inflammatory states. Recent studies with the advanced CSF methodology have confirmed and extended these previous studies in that about 15% of cases with therapy-resistant depression provide evidence of low-grade classical neuroinflammation, about 25% provide evidence of blood-CSF barrier dysfunction [22] and, with some overlap to these pathological findings, about 30% of patients demonstrate inflammatory activation patterns on CSF cells [23]. In addition, more than 30% showed, with little overlap to the other findings, considerably increased CSF-neopterin, likely indicating some immune-inflammatory condition [24].

The Model of 'Sickness Behavior' for Depression

An animal model for MD is 'sickness behavior', i.e. the behavioral, vegetative, cognitive and emotional reaction of an organism to infection and inflammation [25, 26]. In humans, the involvement of cytokines in the regulation of sickness behavior has been studied by administering the bacterial endotoxin lipopolysaccharide, LPS, to healthy volunteers [27]. The levels of anxiety, depression and cognitive impairment were found to be related to the levels of circulating cytokines [27, 28].

The Proinflammatory Immune State in MD

A high blood level of CRP is a common marker for an inflammatory process. Higher than normal CRP levels have been repeatedly observed in depression, for example

in severely depressed inpatients [29], and high CRP levels have been found to be associated with the severity of depression [30]. Higher CRP levels were also observed in remitted patients after a depressive state, in both men [31, 32] and women [33, 34]. In a sample of older healthy persons, CRP levels (and IL-6 levels) were predictive of cognitive symptoms of depression 12 years later [35].

Characteristics of immune activation in MD include increased numbers of circulating lymphocytes and phagocytic cells, upregulated serum levels of markers of immune activation (neopterin, soluble IL-2 receptors), higher serum concentrations of positive acute-phase proteins, APPs, coupled with reduced levels of negative APPs, and increased release of proinflammatory cytokines, such as IL-1 β , IL-2, TNF- α and IL-6 through activated macrophages, and IFN- α through activated T cells [3, 36–41] (table 1). Increased numbers of peripheral mononuclear cells in MD have been described by different research groups [42–44]. In accordance with the findings of increased monocytes and macrophages, an increased level of neopterin has also been described [45–48]. The role of cellular immunity, cytokines, the innate and the adaptive immune system in depression has been recently reviewed [49, 50].

Infections and Autoimmune Disorders as Risk Factors for MD

Results of a very interesting population-based Danish register study support the view that an infection or an autoimmune disease significantly increases the risk of later developing a depressive disorder. This population-based prospective cohort study of 78 million person-years includes 3.6 million registered people (born between 1945 and 1996). The follow-up was documented from 1977 to 2010. All individuals with the diagnosis of an affective disorder according to ICD-8, ICD-9 or ICD-10 were included in case they had had at least one hospital contact as an in- or outpatient due to affective disorder (including bipolar disorder). Every hospital contact due to an autoimmune disorder or infection (excluding HIV/AIDS) prior to psychiatric diagnosis was recorded and >91,000 affective disorder cases were identified, of which ~30,000 were diagnosed with infection and >4,000 were diagnosed with autoimmune disease.

Hospitalization for infection significantly increased the risk of later mood disorder by 62% (incident rate ratio, IRR, 1.62), while hospitalization for autoimmune disease significantly increased the risk of later mood disorder by 45% (IRR 1.45). The interaction of both risk factors increased the risk to IRR 2.35. The risks were higher for

Table 1. Candidates for immune markers related to major depression

Disease-related markers	Markers for anti-depressant response	Markers for response to immune-related therapy
IL-6	IL-6	IL-6
TNF- α	Quinolinic acid	CRP
CRP	TNF- α	TNF- α
Neopterin		TNFR1
		TNFR2
		Kynurenine/tryptophan

hepatitis infection (IRR 2.82) compared to sepsis or CNS infections. The risk of mood disorder increased with the proximity to the infection, with the highest risk within the first year (IRR 2.70) [51].

Inflammation Influences the Metabolism of Serotonin and Noradrenalin in Depression

Overwhelming evidence collected over the last 40 years suggests that disturbances in serotonergic and noradrenergic neurotransmission are crucial factors in the pathogenesis of MD [52, 53]. Although the pathogenesis of the disturbed serotonergic and noradrenergic mechanisms is still unclear, the involvement of the proinflammatory immune state might be crucial. The proinflammatory cytokine IL-1 β increases the metabolism of serotonin and noradrenalin within the hypothalamus, prefrontal cortex, hippocampus and amygdala [54–59]. Similar but less pronounced effects on central monoamine activity after stimulation with LPS or poly:IC have been observed for several mediators such as IL-6 and TNF- α [59, 60].

Similarly, administration of the proinflammatory cytokine IFN- α is associated with reduced levels of serotonin in the prefrontal cortex [61]. Accordingly, symptoms of depression have been observed in many patients treated with IFN- α [62, 63].

Moreover, two indirect pathways of the tryptophan/kynurenine metabolism contribute to the induction of symptoms of depression by proinflammatory cytokines: (1) the increased metabolism of serotonin and (2) the increased production of N-methyl-D-aspartate (NMDA) agonists, i.e. glutamatergic products of kynurenine metabolism, after activation of the enzyme indoleamine 2,3-dioxygenase (IDO) by proinflammatory cytokines [64, 65]. Proinflammatory molecules such as PGE2 or TNF- α , however, induce the increase of IDO activity synergistically with IFN [66–68].

Increased activity of the glutamatergic system in the peripheral blood of depressive patients has been repeatedly shown [69–71], although this result could not be replicated by all groups [72]. The inconsistency of the findings, however, might be due to methodological problems [73]. Support for increased glutamatergic activity in depression comes from magnetic resonance spectroscopy: elevated glutamate levels were found in the occipital cortex of unmedicated subjects with MD [74]. Furthermore, NMDA antagonists such as MK-801 [75, 76], ketamine [77], memantine [78], amantadine [79, 80] and others [73] have exhibited antidepressant effects in humans. The partial NMDA receptor agonist D-cycloserine demonstrated antidepressant effects at high doses [81].

Several mechanisms can cause depressive states: (1) a direct influence of proinflammatory cytokines on serotonin and noradrenalin metabolism [60, 82, 83]; (2) an imbalance of the type 1 and type 2 immune responses leading to increased tryptophan and serotonin metabolism by activation of IDO in the CNS [84, 85]; (3) a decreased availability of tryptophan and serotonin [47], and (4) a disturbance of kynurenine metabolism, with an imbalance in favor of the production of the NMDA receptor agonist quinolinic acid [85, 86].

CNS Volume Loss in Neuroimaging Studies – A Consequence of an Inflammatory Process?

A loss of brain volume has been observed in MD. Male patients with a first episode of MD had significantly smaller hippocampal total and grey matter volumes than healthy male comparison subjects [87]. In a long-term study a significantly higher decline of volume in several CNS regions compared to healthy controls was observed [88]. The pathophysiology of this volume loss is unclear. Glial reductions have been consistently found in brain circuits known to be involved in mood disorders, such as the limbic and prefrontal cortex [89–93]. Recent studies have shown that the number of astrocytes is reduced in patients suffering from MD [94–96], although the data are not fully consistent [97].

COX-2 Inhibition as an Example for an Anti-Inflammatory Therapeutic Approach in MD

COX-2 inhibitors influence the CNS serotonergic system, either directly or via CNS immune mechanisms. In a rat model, treatment with rofecoxib was followed by an

increase of serotonin in the frontal and the temporoparietal cortex [98]. Therefore, COX-2 inhibitors would be expected to show a clinical antidepressant effect. In the depression animal model of the bulbectomized rat, a decrease in hypothalamic cytokine levels and a change in behavior have been observed after chronic celecoxib treatment [99]. In another animal model of depression, however, the mixed COX-1/COX-2 inhibitor acetylsalicylic acid showed an additional antidepressant effect by accelerating the antidepressant effect of fluoxetine [100]. A significant therapeutic effect of the COX-2 inhibitor celecoxib in MD was also found in a randomized, double-blind pilot add-on study of reboxetine and celecoxib versus reboxetine versus placebo [101]. Interestingly, the ratio of kynurenine to tryptophan, which represents the activity of the proinflammatory cytokine-driven enzyme IDO, predicted the antidepressant response to the celecoxib therapy. Patients with a high activity of IDO, i.e. a high proinflammatory activity, responded better to celecoxib [Müller et al., submitted]. Another randomized, double-blind study in 50 depressed patients suffering from MD also showed a significantly better outcome with the COX-2 inhibitor celecoxib plus fluoxetine than with fluoxetine alone [102, 103]. This finding was recently replicated using the combination of sertraline and celecoxib in 40 depressed patients [103]. Interestingly, the blood levels of IL-6 predicted the antidepressant response both in the sertraline (plus placebo) group and in the celecoxib (plus sertraline) group.

The anti-TNF- α antibody infliximab, which blocks the interaction of TNF- α with cell-surface receptors and was developed for the therapy of inflammatory joint disorders and psoriasis, showed a highly significant effect on symptoms of depression in psoriasis patients [104]. In a placebo-controlled add-on study using infliximab, however, an overall antidepressant effect could not be shown in a study of treatment-resistant depressed patients. Three infusions of infliximab or placebo were given in a 12-week trial ($n = 60$) in partly medication-free ($n = 23$) nonresponders to antidepressant therapy. No overall better outcome of infliximab versus placebo could be shown. There was, however, a significant interaction between treatment, time and baseline CRP (≤ 5 mg/l): patients with higher baseline CRP had a higher response rate to infliximab (62%) versus placebo (33%). Moreover, the baseline concentrations of TNF- α , sTNFR1 and sTNFR2 were significantly higher in infliximab responders ($p \leq 0.01$). Additionally, infliximab responders exhibited a significantly higher decrease of CRP ($p \leq 0.01$) than nonresponders [105]. Interestingly, there are also preliminary

findings that the angiotensin II AT1 receptor blockade has anti-inflammatory effects in the CNS and ameliorates stress, anxiety and CNS inflammation [106, 107].

Inflammatory Pathogenesis in MD and Schizophrenia – The End of the Kraepelinian Dichotomy?

The Kraepelinian dichotomy of schizophrenia and affective disorder has been discussed for many years. Several findings of modern biological psychiatry show an overlap of both disorders and genetic researchers postulate, in particular, that new diagnostic classifications which have greater biological validity will in the future allow the selection of treatments based on the underlying pathogenesis [108]. With respect to the mechanisms of inflammation, different patterns of type 1 and type 2 immune activation seem to be associated with schizophrenia versus MD [109]. The large table of immune and inflammatory genes involved makes it plausible that various types of immune balance may be involved. Differences in immune activation may have different impacts on the IDO activation and the tryptophan/kynurenine metabolism, which then may result in increased production of kynurenic acid in schizophrenia and increased quinolinic acid levels in depression. Such differences may be associated with an imbalance in the glutamatergic neurotransmission, contributing to an exaggerated NMDA activity in depression and NMDA antagonism in schizophrenia. Moreover, differential activation of microglia cells and astrocytes in schizophrenia and depression may be an additional mechanism to increased production of PGE2 and increased expression of COX-2.

Although there is strong evidence for the view that the interactions of the immune system, IDO, serotonergic system and glutamatergic neurotransmission play a key

role in schizophrenia and depression, several gaps, for example the roles of genetics, disease course, sex, different psychopathological states, etc., have to be bridged by further intense research. Moreover, COX-2 inhibition is only one example of possible therapeutic mechanisms acting on these mechanisms. Also, the effects of COX-2 inhibition in the CNS as well as the different components of the inflammatory system, the kynurenine metabolism and the glutamatergic neurotransmission need further careful scientific evaluation.

Moreover, similar pathological influences may lead to different psychopathological states due to different localizations of the pathological processes in the CNS. Neuropathological and neuroimaging studies show that – albeit with a broad range of overlap – different brain regions are involved in schizophrenia (e.g. the hippocampus [110, 111]) and depression (e.g. the habenula [112, 113]).

Despite some common pathways, different final pathways may lead to different syndromes of schizophrenia and depression. Inflammation, including low-grade inflammation, is a general pathway of the body representing a response to a lot of different noxae and pathogens. Despite some overlap, which is apparent between pathophysiological mechanisms identified in schizophrenia and affective disorders, the differential mechanisms are also of major interest. Similar phenomena, overlap and some specificity are found in medicine in general, and not only in psychiatry. To develop preventive strategies in high-risk individuals and patients [114], such refined understanding is of immense interest.

Acknowledgement

Parts of this paper have been published before [115, 116].

References

- 1 Maes M: Cytokines in major depression. *Biol Psychiatry* 1994;36:498–499.
- 2 Maes M, Stevens W, DeClerck L, Bridts C, Peeters D, Schotte C, Cosyns P: Immune disorders in depression: higher T helper/T suppressor-cytotoxic cell ratio. *Acta Psychiatrica Scand* 1992;86:423–431.
- 3 Müller N, Hofschuster E, Ackenheil M, Mempel W, Eckstein R: Investigations of the cellular immunity during depression and the free interval: evidence for an immune activation in affective psychosis. *Prog Neuropsychopharmacol Biol Psychiatry* 1993;17:713–730.
- 4 Myint AM, Leonard BE, Steinbusch HW, Kim YK: Th1, Th2, and Th3 cytokine alterations in major depression. *J Affect Disord* 2005;88:167–173.
- 5 Rothermundt M, Arolt V, Peters M, Gutbrodt H, Fenker J, Kersting A, Kirchner H: Inflammatory markers in major depression and melancholia. *J Affect Disord* 2001;63:93–102.
- 6 Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, Lanctot KL: A meta-analysis of cytokines in major depression. *Biol Psychiatry* 2010;67:446–457.

- 7 Howren MB, Lamkin DM, Suls J: Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. *Psychosom Med* 2009;71:171–186.
- 8 Song C, Lin A, Bonaccorso S, Heide C, Verkerk R, Kenis G, Bosmans E, Scharpe S, Whelan A, Cosyns P, De Jongh R, Maes M: The inflammatory response system and the availability of plasma tryptophan in patients with primary sleep disorders and major depression. *J Affect Disord* 1998;49:211–219.
- 9 Calabrese JR, Skwerer RG, Barna B, Gullledge AD, Valenzuela R, Butkus A, Subichin S, Krupp NE: Depression, immunocompetence, and prostaglandins of the E series. *Psychiatry Res* 1986;17:41–47.
- 10 Linnoila M, Whorton AR, Rubinow DR, Cowdry RW, Ninan PT, Waters RN: CSF prostaglandin levels in depressed and schizophrenic patients. *Arch Gen Psychiatry* 1983;40:405–406.
- 11 Nishino S, Ueno R, Ohishi K, Sakai T, Hayashi O: Salivary prostaglandin concentrations: possible state indicators for major depression. *Am J Psychiatry* 1989;146:365–368.
- 12 Ohishi K, Ueno R, Nishino S, Sakai T, Hayashi O: Increased level of salivary prostaglandins in patients with major depression. *Biol Psychiatry* 1988;23:326–334.
- 13 Brambilla R, Bracchi-Ricard V, Hu WH, Frydel B, Bramwell A, Karmally S, Green EJ, Bethea JR: Inhibition of astroglial nuclear factor κ B reduces inflammation and improves functional recovery after spinal cord injury. *J Exp Med* 2005;202:145–156.
- 14 Farina C, Aloisi F, Meinl E: Astrocytes are active players in cerebral innate immunity. *Trends Immunol* 2007;28:138–145.
- 15 Gao HM, Hong JS: Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression. *Trends Immunol* 2008;29:357–365.
- 16 Aronica E, Gorter JA, Ijlst-Keizers H, Roze-muller AJ, Yankaya B, Leenstra S, Troost D: Expression and functional role of mGluR3 and mGluR5 in human astrocytes and glioma cells: opposite regulation of glutamate transporter proteins. *Eur J Neurosci* 2003;17:2106–2118.
- 17 Wildemann B, Oschmann P, Reiber H: *Laboratory Diagnosis in Neurology*. Stuttgart, Thieme, 2010.
- 18 Schwartz M, Shechter R: Protective autoimmunity functions by intracranial immunosurveillance to support the mind: the missing link between health and disease. *Mol Psychiatry* 2010;15:342–354.
- 19 Hampel H, Muller SF, Berger C, Haberl A, Ackenheil M, Hock C: Evidence of blood-cerebrospinal fluid-barrier impairment in a subgroup of patients with dementia of the Alzheimer type and major depression: a possible indicator for immunoactivation. *Dementia* 1995;6:348–354.
- 20 Hampel H, Kotter HU, Moller HJ: Blood-cerebrospinal fluid barrier dysfunction for high molecular weight proteins in Alzheimer disease and major depression: indication for disease subsets. *Alzheimer Dis Assoc Disord* 1997;11:78–87.
- 21 Hampel H, Kotter HU, Padberg F, Korschenhausen DA, Moller HJ: Oligoclonal bands and blood: cerebrospinal-fluid barrier dysfunction in a subset of patients with Alzheimer disease: comparison with vascular dementia, major depression, and multiple sclerosis. *Alzheimer Dis Assoc Disord* 1999;13:9–19.
- 22 Bechter K, Reiber H, Herzog S, Fuchs D, Tuman H, Maxeiner HG: Cerebrospinal fluid analysis in affective and schizophrenic spectrum disorders: identification of subgroups with immune responses and blood-CSF barrier dysfunction. *J Psychiatr Res* 2010;44:321–330.
- 23 Maxeiner HG, Rojewski MT, Schmitt A, Tuman H, Bechter K, Schmitt M: Flow cytometric analysis of T cell subsets in paired samples of cerebrospinal fluid and peripheral blood from patients with neurological and psychiatric disorders. *Brain Behav Immun* 2009;23:134–142.
- 24 Kuehne LK, Reiber H, Bechter K, Hagberg L, Fuchs D: Cerebrospinal fluid neopterin is brain-derived and not associated with blood CSF barrier dysfunction in non-inflammatory affective and schizophrenic spectrum disorders. *J Psychiatr Res* 2013;47:1417–1422.
- 25 Dantzer R: Cytokine-induced sickness behavior: where do we stand? *Brain Behav Immun* 2001;15:7–24.
- 26 Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW: From inflammation to sickness and depression: when the immune system subjugates the brain. *Nat Rev Neurosci* 2008;9:46–56.
- 27 Reichenberg A, Yirmiya R, Schuld A, Kraus T, Haack M, Morag A, Pollmacher T: Cytokine-associated emotional and cognitive disturbances in humans. *Arch Gen Psychiatry* 2001;58:445–452.
- 28 Reichenberg A, Kraus T, Haack M, Schuld A, Pollmacher T, Yirmiya R: Endotoxin-induced changes in food consumption in healthy volunteers are associated with TNF- α and IL-6 secretion. *Psychoneuroendocrinology* 2002;27:945–956.
- 29 Lanquillon S, Krieg JC, Bening-Abu-Shach U, Vedder H: Cytokine production and treatment response in major depressive disorder. *Neuropsychopharmacology* 2000;22:370–379.
- 30 Häfner S, Baghai TC, Eser D, Schüle C, Rupprecht R, Bondy B, Bedarida G, von SC: C-reactive protein is associated with polymorphisms of the angiotensin-converting enzyme gene in major depressed patients. *J Psychiatr Res* 2008;42:163–165.
- 31 Danner M, Kasl SV, Abramson JL, Vaccarino V: Association between depression and elevated C-reactive protein. *Psychosom Med* 2003;65:347–356.
- 32 Ford DE, Erlinger TP: Depression and C-reactive protein in US adults: data from the Third National Health and Nutrition Examination Survey. *Arch Intern Med* 2004;164:1010–1014.
- 33 Kling MA, Alesci S, Csako G, Costello R, Luckenbaugh DA, Bonne O, Duncko R, Drevets WC, Manji HK, Charney DS, Gold PW, Neumeister A: Sustained low-grade pro-inflammatory state in unmedicated, remitted women with major depressive disorder as evidenced by elevated serum levels of the acute phase proteins C-reactive protein and serum amyloid A. *Biol Psychiatry* 2007;62:309–313.
- 34 Cizza G, Eskandari F, Coyle M, Krishnamurthy P, Wright EC, Mistry S, Csako G: Plasma CRP levels in premenopausal women with major depression: a 12-month controlled study. *Horm Metab Res* 2009;41:641–648.
- 35 Gimeno D, Marmot MG, Singh-Manoux A: Inflammatory markers and cognitive function in middle-aged adults: the Whitehall II study. *Psychoneuroendocrinology* 2008;33:1322–1334.
- 36 Maes M, Meltzer HY, Bosmans E, Bergmans R, Vandoolaeghe E, Ranjan R, Desnyder R: Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. *J Affect Disord* 1995;34:301–309.
- 37 Maes M, Meltzer HY, Buckley P, Bosmans E: Plasma-soluble interleukin-2 and transferrin receptor in schizophrenia and major depression. *Eur Arch Psychiatry Clin Neurosci* 1995;244:325–329.
- 38 Irwin M: Immune correlates of depression. *Adv Exp Med Biol* 1999;461:1–24.
- 39 Nunes SOV, Reiche EMV, Morimoto HK, Matsuo T, Itano EN, Xavier ECD, Yamashita CM, Vieira VR, Menoli AV, Silva SS, Costa FB, Reiche FV, Silva FLV, Kaminami MS: Immune and hormonal activity in adults suffering from depression. *Braz J Med Biol Res* 2002;35:581–587.
- 40 Müller N, Schwarz MJ: Immunology in anxiety and depression; in Kasper S, den Boer JA, Sitsen JMA (eds): *Handbook of Depression and Anxiety*. New York, Marcel Dekker, 2002, pp 267–288.
- 41 Mikova O, Yakimova R, Bosmans E, Kenis G, Maes M: Increased serum tumor necrosis factor alpha concentrations in major depression and multiple sclerosis. *Eur Neuropsychopharmacol* 2001;11:203–208.
- 42 Herbert TB, Cohen S: Depression and immunity: a meta-analytic review. *Psychol Bull* 1993;113:472–486.
- 43 Seidel A, Arolt V, Hunstiger M, Rink L, Behnisch A, Kirchner H: Major depressive disorder is associated with elevated monocyte counts. *Acta Psychiatr Scand* 1996;94:198–204.

- 44 Rothermundt M, Arolt V, Fenker J, Gutbrodt H, Peters M, Kirchner H: Different immune patterns in melancholic and non-melancholic major depression. *Eur Arch Psychiatry Clin Neurosci* 2001;251:90–97.
- 45 Duch DS, Woolf JH, Nichol CA, Davidson JR, Garbutt JC: Urinary excretion of biopterin and neopterin in psychiatric disorders. *Psychiatry Res* 1984;11:83–89.
- 46 Dunbar PR, Hill J, Neale TJ, Mellsop GW: Neopterin measurement provides evidence of altered cell-mediated immunity in patients with depression, but not with schizophrenia. *Psychol Med* 1992;22:1051–1057.
- 47 Maes M, Scharpe S, Meltzer HY, Okayli G, Bosmans E, D'Hondt P, Vanden Bossche BV, Cosyns P: Increased neopterin and interferon-gamma secretion and lower availability of L-tryptophan in major depression: further evidence for an immune response. *Psychiatry Res* 1994;54:143–160.
- 48 Bonaccorso S, Lin AH, Verkerk R, Van Hunsel F, Libbrecht I, Scharpe S, DeClerck L, Biondi M, Janca A, Maes M: Immune markers in fibromyalgia: comparison with major depressed patients and normal volunteers. *J Affect Disord* 1998;48:75–82.
- 49 Müller N, Myint AM, Schwarz MJ: Inflammatory biomarkers and depression. *Neurotox Res* 2011;19:308–318.
- 50 Maes M: Depression is an inflammatory disease, but cell-mediated immune activation is the key component of depression. *Prog Neuropsychopharmacol Biol Psychiatry* 2011;35:664–675.
- 51 Benros ME, Waltoft BL, Nordentoft M, Ostergaard SD, Eaton WW, Krogh J, Mortensen PB: Autoimmune diseases and severe infections as risk factors for mood disorders: a nationwide study. *JAMA Psychiatry* 2013;70:812–820.
- 52 Matussek N: *Neurobiologie und Depression*. *Med Monatsschr* 1966;3:109–112.
- 53 Coppen A, Swade C: 5-HT and depression: the present position; in Briley M, Fillion G (eds): *New Concepts in Depression: Pierre Fabre Monograph Series*. London, MacMillan Press, 1988, pp 120–136.
- 54 Anisman H, Merali Z: Anhedonic and anxiogenic effects of cytokine exposure. *Adv Exp Med Biol* 1999;461:199–233.
- 55 Day HE, Curran EJ, Watson SJ Jr, Akil H: Distinct neurochemical populations in the rat central nucleus of the amygdala and bed nucleus of the stria terminalis: evidence for their selective activation by interleukin-1 β . *J Comp Neurol* 1999;413:113–128.
- 56 Linthorst AC, Flachskamm C, Muller Preuss P, Holsboer F, Reul JM: Effect of bacterial endotoxin and interleukin-1 β on hippocampal serotonergic neurotransmission, behavioral activity, and free corticosterone levels: an in vivo microdialysis study. *J Neurosci* 1995;15:2920–2934.
- 57 Merali Z, Lacosta S, Anisman H: Effects of interleukin-1 β and mild stress on alterations of norepinephrine, dopamine and serotonin neurotransmission: a regional microdialysis study. *Brain Res* 1997;761:225–235.
- 58 Shintani F, Nakaki T, Kanba S, Sato K, Yagi G, Shiozawa M, Aiso S, Kato R, Asai M: Involvement of interleukin-1 in immobilization stress-induced increase in plasma adrenocorticotropic hormone and in release of hypothalamic monoamines in the rat. *J Neurosci* 1995;15:1961–1970.
- 59 Song C, Merali Z, Anisman H: Variations of nucleus accumbens dopamine and serotonin following systemic interleukin-1, interleukin-2 or interleukin-6 treatment. *Neuroscience* 1999;88:823–836.
- 60 Zalcman S, Green-Johnson JM, Murray L, Nance DM, Dyck D, Anisman H, Greenberg AH: Cytokine-specific central monoamine alterations induced by interleukin-1, -2 and -6. *Brain Res* 1994;643:40–49.
- 61 Asnis GM, De La GR, Kohn SR, Reinus JF, Henderson M, Shah J: IFN-induced depression: a role for NSAIDs. *Psychopharmacol Bull* 2003;37:29–50.
- 62 Raison CL, Capuron L, Miller AH: Cytokines sing the blues: inflammation and the pathogenesis of depression. *Trends Immunol* 2006;27:24–31.
- 63 Schäfer M, Horn M, Schmidt F, Schmid-Wendtner MH, Volkenandt M, Ackenheil M, Müller N, Schwarz MJ: Correlation between sICAM-1 and depressive symptoms during adjuvant treatment of melanoma with interferon- α . *Brain Behav Immun* 2004;18:555–562.
- 64 Müller N, Schwarz MJ, Riedel M: COX-2 inhibition in schizophrenia: focus on clinical effects of celecoxib therapy and the role of TNF- α ; in Eaton WW (ed): *Medical and Psychiatric Comorbidity over the Course of Life*. Washington, American Psychiatric Publishing, 2005, pp 265–276.
- 65 Müller N, Schwarz MJ: The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. *Mol Psychiatry* 2007;12:988–1000.
- 66 Braun D, Longman RS, Albert ML: A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic-cell maturation. *Blood* 2005;106:2375–2381.
- 67 Kwidzinski E, Bunse J, Aktas O, Richter D, Mutlu L, Zipp F, Nitsch R, Bechmann I: Indoleamine 2,3-dioxygenase is expressed in the CNS and down-regulates autoimmune inflammation. *FASEB J* 2005;19:1347–1349.
- 68 Robinson CM, Hale PT, Carlin JM: The role of IFN- γ and TNF- α -responsive regulatory elements in the synergistic induction of indoleamine dioxygenase. *J Interferon Cytokine Res* 2005;25:20–30.
- 69 Kim JS, Schmid-Burgk W, Claus D, Kornhuber HH: Increased serum glutamate in depressed patients. *Arch Psychiatr Nervenkr* 1982;232:299–304.
- 70 Altamura CA, Mauri MC, Ferrara A, Moro AR, D'Andrea G, Zamberlan F: Plasma and platelet excitatory amino acids in psychiatric disorders. *Am J Psychiatry* 1993;150:1731–1733.
- 71 Mauri MC, Ferrara A, Boscati L, Bravin S, Zamberlan F, Alecci M, Invernizzi G: Plasma and platelet amino acid concentrations in patients affected by major depression and under fluvoxamine treatment. *Neuropsychobiology* 1998;37:124–129.
- 72 Maes M, Verkerk R, Vandoolaeghe E, Lin A, Scharpe S: Serum levels of excitatory amino acids, serine, glycine, histidine, threonine, taurine, alanine and arginine in treatment-resistant depression: modulation by treatment with antidepressants and prediction of clinical responsiveness. *Acta Psychiatr Scand* 1998;97:302–308.
- 73 Kugaya A, Sanacora G: Beyond monoamines: glutamatergic function in mood disorders. *CNS Spectr* 2005;10:808–819.
- 74 Sanacora G, Gueorguieva R, Epperson CN, Wu YT, Appel M, Rothman DL, Krystal JH, Mason GF: Subtype-specific alterations of γ -aminobutyric acid and glutamate in patients with major depression. *Arch Gen Psychiatry* 2004;61:705–713.
- 75 Maj J, Rogoz Z, Skuza G, Sowinska H: Effects of MK-801 and antidepressant drugs in the forced swimming test in rats. *Eur Neuropsychopharmacol* 1992;2:37–41.
- 76 Trullas R, Skolnick P: Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. *Eur J Pharmacol* 1990;185:1–10.
- 77 Yilmaz A, Schulz D, Aksoy A, Canbeyli R: Prolonged effect of an anesthetic dose of ketamine on behavioral despair. *Pharmacol Biochem Behav* 2002;71:341–344.
- 78 Ossowska G, Klenk-Majewska B, Szymczyk G: The effect of NMDA antagonists on foot-shock-induced fighting behavior in chronically stressed rats. *J Physiol Pharmacol* 1997;48:127–135.
- 79 Huber TJ, Dietrich DE, Emrich HM: Possible use of amantadine in depression. *Pharmacopsychiatry* 1999;32:47–55.
- 80 Stryjer R, Strous RD, Shaked G, Bar F, Feldman B, Kotler M, Polak L, Rosenczwaig S, Weizman A: Amantadine as augmentation therapy in the management of treatment-resistant depression. *Int Clin Psychopharmacol* 2003;18:93–96.
- 81 Crane G: Cyloserine as an antidepressant agent. *Am J Psychiatry* 1959;115:1025–1026.
- 82 Song C, Leonard BE: *Fundamentals of psychoneuroimmunology*. Chichester, J Wiley and Sons, 2000.
- 83 Besedovsky H, del RA, Sorkin E, Da PM, Burri R, Honegger C: The immune response evokes changes in brain noradrenergic neurons. *Science* 1983;221:564–566.
- 84 Schwarz MJ, Chiang S, Müller N, Ackenheil M: T-helper-1 and T-helper-2 responses in psychiatric disorders. *Brain Behav Immun* 2001;15:340–370.

- 85 Myint AM, Kim YK: Cytokine-serotonin interaction through IDO: a neurodegeneration hypothesis of depression. *Med Hypotheses* 2003;61:519–525.
- 86 Myint AM, Kim YK, Verkerk R, Scharpe S, Steinbusch H, Leonard B: Kynurenine pathway in major depression: evidence of impaired neuroprotection. *J Affect Disord* 2007;98:143–151.
- 87 Frodl T, Meisenzahl EM, Zetzsche T, Born C, Groll C, Jager M, Leinsinger G, Bottlender R, Hahn K, Moller HJ: Hippocampal changes in patients with a first episode of major depression. *Am J Psychiatry* 2002;159:1112–1118.
- 88 Frodl TS, Koutsouleris N, Bottlender R, Born C, Jager M, Scupin I, Reiser M, Moller HJ, Meisenzahl EM: Depression-related variation in brain morphology over 3 years: effects of stress? *Arch Gen Psychiatry* 2008;65:1156–1165.
- 89 Cotter D, Pariante C, Rajkowska G: Glial pathology in major psychiatric disorders; in Agam G, Belmaker RH, Everall I (eds): *The Post-Mortem Brain in Psychiatric Research*. Boston, Kluwer Academic Pub, 2002, pp 291–324.
- 90 Ongur D, Drevets WC, Price JL: Glial reduction in the subgenual prefrontal cortex in mood disorders. *Proc Natl Acad Sci USA* 1998;95:13290–13295.
- 91 Rajkowska G, Miguel-Hidalgo JJ, Wei J, Dilley G, Pittman SD, Meltzer HY, Overholser JC, Roth BL, Stockmeier CA: Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. *Biol Psychiatry* 1999;45:1085–1098.
- 92 Rajkowska G, Halaris A, Selemon LD: Reductions in neuronal and glial density characterize the dorsolateral prefrontal cortex in bipolar disorder. *Biol Psychiatry* 2001;49:741–752.
- 93 Rajkowska G: Depression: what we can learn from postmortem studies. *Neuroscientist* 2003;9:273–284.
- 94 Johnston-Wilson NL, Sims CD, Hofmann J-P, Anderson L, Shore AD, Torrey EF, Yolken RH: Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder. *Mol Psychiatry* 2000;5:142–149.
- 95 Miguel-Hidalgo JJ, Baucom C, Dilley G, Overholser JC, Meltzer HY, Stockmeier CA, Rajkowska G: Glial fibrillary acidic protein immunoreactivity in the prefrontal cortex distinguishes younger from older adults in major depressive disorder. *Biol Psychiatry* 2000;48:861–873.
- 96 Si X, Miguel-Hidalgo JJ, O'Dwyer G, Stockmeier CA, Rajkowska G: Age-dependent reductions in the level of glial fibrillary acidic protein in the prefrontal cortex in major depression. *Neuropsychopharmacology* 2004;29:2088–2096.
- 97 Davis S, Thomas A, Perry R, Oakley A, Kalaria RN, O'Brien JT: Glial fibrillary acidic protein in late life major depressive disorder: an immunocytochemical study. *J Neurol Neurosurg Psychiatry* 2002;73:556–560.
- 98 Sandrini M, Vitale G, Pini LA: Effect of rofecoxib on nociception and the serotonin system in the rat brain. *Inflamm Res* 2002;51:154–159.
- 99 Myint AM, Steinbusch HW, Goeghegan L, Luchtman D, Kim YK, Leonard BE: Effect of the COX-2 inhibitor celecoxib on behavioural and immune changes in an olfactory bulbectomised rat model of depression. *Neuroimmunomodulation* 2007;14:65–71.
- 100 Brunello N, Alboni S, Capone G, Benatti C, Blom JM, Tascetta F, Kriwin P, Mendlewicz J: Acetylsalicylic acid accelerates the antidepressant effect of fluoxetine in the chronic escape deficit model of depression. *Int Clin Psychopharmacol* 2006;21:219–225.
- 101 Müller N, Schwarz MJ, Dehning S, Douhet A, Cerovecki A, Goldstein-Müller B, Spellmann I, Hetzel G, Maino K, Kleindienst N, Möller HJ, Arolt V, Riedel M: The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. *Mol Psychiatry* 2006;11:680–684.
- 102 Akhondzadeh S, Jafari S, Raisi F, Ghoreishi A, Salehi B, Mohebbi-Rasa S, Raznahan M, Kamalipour A: Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. *Depress Anxiety* 2009;26:607–611.
- 103 Abbasi SH, Hosseini F, Modabbernia A, Ashrafi M, Akhondzadeh S: Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study. *J Affect Disord* 2012;141:308–314.
- 104 Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, Lalla D, Woolley M, Jahreis A, Zitnik R, Cella D, Krishnan R: Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. *Lancet* 2006;367:29–35.
- 105 Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF, Haroon E, Miller AH: A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. *JAMA Psychiatry* 2013;70:31–41.
- 106 Benicky J, Sanchez-Lemus E, Honda M, Pang T, Orecna M, Wang J, Leng Y, Chuang DM, Saavedra JM: Angiotensin II AT₁ receptor blockade ameliorates brain inflammation. *Neuropsychopharmacology* 2011;36:857–870.
- 107 Saavedra JM, Sanchez-Lemus E, Benicky J: Blockade of brain angiotensin II AT₁ receptors ameliorates stress, anxiety, brain inflammation and ischemia: therapeutic implications. *Psychoneuroendocrinology* 2011;36:1–18.
- 108 Craddock N, Owen MJ: The Kraepelinian dichotomy – going, going... but still not gone. *Br J Psychiatry* 2010;196:92–95.
- 109 Müller N: Immunology of schizophrenia. *Neuroimmunomodulation* 2014;21:109–116.
- 110 Dutt A, Ganguly T, Shaikh M, Walshe M, Schulze K, Marshall N, Constante M, McDonald C, Murray RM, Allin MP, Bramon E: Association between hippocampal volume and P300 event related potential in psychosis: support for the Kraepelinian divide. *Neuroimage* 2012;59:997–1003.
- 111 Radonic E, Rados M, Kalember P, Bajs-Janovic M, Folnegovic-Smalc V, Henigsberg N: Comparison of hippocampal volumes in schizophrenia, schizoaffective and bipolar disorder. *Coll Antropol* 2011;35(suppl 1):249–252.
- 112 Savitz JB, Nugent AC, Bogers W, Roiser JP, Bain EE, Neumeister A, Zarate CA Jr, Manji HK, Cannon DM, Marrett S, Henn F, Charney DS, Drevets WC: Habenula volume in bipolar disorder and major depressive disorder: a high-resolution magnetic resonance imaging study. *Biol Psychiatry* 2011;69:336–343.
- 113 Winter C, Vollmayr B, Djodari-Irani A, Klein J, Sartorius A: Pharmacological inhibition of the lateral habenula improves depressive-like behavior in an animal model of treatment resistant depression. *Behav Brain Res* 2011;216:463–465.
- 114 Müller N, Schwarz MJ: A psychoneuroimmunological perspective to Emil Kraepelin's dichotomy: schizophrenia and major depression as inflammatory CNS disorders. *Eur Arch Psychiatry Clin Neurosci* 2008;258(suppl 2):97–106.
- 115 Müller N: Infectious diseases and mental health; in Sartorius N, Maj M, Holt R (eds): *Comorbidity of Mental and Physical Disorders. Key Issues Ment Health*. Basel, Karger, 2014, vol 180 (in press).
- 116 Müller N, Bechter K: The mild encephalitis concept for psychiatric disorders revisited in the light of current psychoneuroimmunological findings. *Neurology, Psychiatry and Brain Research* 2013;19:87–101.